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Abstract Therapeutic cell retention and engraftment are
critical for myocardial regeneration. Underlying mecha-
nisms, including the role of tissue perfusion, are not well
understood. In Wistar Kyoto rats, syngeneic cardiosphere-
derived cells (CDCs) were injected intramyocardially, after
experimental myocardial infarction. CDCs were labeled
with [
18F]-FDG (n = 7), for quantiﬁcation of 1-h retention,
or with sodium-iodide-symporter gene (NIS; n = 8), for
detection of 24-h engraftment by reporter imaging. Perfu-
sion was imaged simultaneously. Infarct size was 37 ± 9
and 38 ± 9% of LV in FDG and NIS groups. Cell signal
was located in the infarct border zone in all animals. No
signiﬁcant relationship was observed between infarct size
and 1-h CDC retention (r =- 0.65; P = 0.11). However,
infarct size correlated signiﬁcantly with 24-h engraftment
(r = 0.75; P = 0.03). Residual perfusion at the injection
site was not related to cell retention/engraftment. Larger
infarcts are associated with improved CDC engraftment.
This observation encourages further investigation of
microenvironmental conditions after ischemic damage and
their role in therapeutic cell survival.
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Introduction
The clinical beneﬁt of cardiac cell transplantation has been
debated [19]. Several studies have observed that only a
small fraction of transplanted cells survives in the injured
heart [10, 23, 27]. Accordingly, strategies to optimize the
therapeutic value of cell transplantation are being
explored. Those include promoting cell proliferation and
differentiation, and augmenting cell survival and engraft-
ment [23, 28]. There is increasing evidence that the tissue
environment is a critical determinant of the fate of stem
cells after delivery. Some signaling molecules, including
inﬂammatory markers, adhesion molecules, and hypoxia
markers are temporarily over-expressed after myocardial
infarction and seem to be involved in therapeutic cell
survival [6, 13]. It is hoped that an improved understanding
of the interaction between host tissue and exogenous
therapeutic cells can be used to improve the regenerative
beneﬁt of cell therapy.
Noninvasive molecular imaging can contribute in this
regard. PET, SPECT and MRI techniques have been
developed to follow the fate of cells [2, 3]. Additionally,
these methods enable simultaneous characterization of the
host tissue through interrogation of perfusion, viability or
other molecular events. Integrated analysis of imaging
signals may not only be helpful in deﬁning the interaction
between host tissue and cell survival. It may also help to
establish a future use of tissue imaging to guide regener-
ative therapy with regards to the optimal time point, patient
group and myocardial region for cell delivery.
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DOI 10.1007/s00395-011-0197-5In this report, we present a ﬁrst step towards integrated
analysis of host tissue conditions and stem cell engraftment,
by investigating the relationship between myocardial per-
fusion and the engraftment of an innovative therapeutic cell
type, cardiosphere-derived cells (CDCs) [1, 14, 20, 24].
Materials and methods
Cell preparation
CDCs were cultured from tissue samples derived from
explanted hearts from male Wistar Kyoto rats, as previ-
ously described [24]. Wistar Kyoto rats are inbred synge-
neic animals and therefore appropriate for use in cell
transplantation studies, without the need for immunosup-
pression. In brief, CDCs were prepared by cutting tissue
samples into small pieces, digesting them with trypsin and
culturing them on ﬁbronectin-coated tissue culture dishes
using complete explant media [24]. Fibroblast-like adher-
ent cells and a smaller number of phase-bright cells migrate
from the explants. The latter cells are collected by washing,
then seeded in poly-D-lysine coated plates, using speciﬁc
media as previously described [24]. Under these condi-
tions, cells aggregate in cardiospheres, which are har-
vested, seeded in ﬁbronectin-coated tissue culture ﬂasks for
expansion as monolayers and cultured in CEM. For in vivo
injection, CDCs were resuspended in 120 ll of PBS.
Animal protocol
Syngeneic Wistar Kyoto rats (n = 15) were utilized for all
experiments. Myocardial infarction was induced by perma-
nent ligation of the left anterior descending coronary artery,
immediately followed by direct intramyocardial injection of
CDCs, as described previously [26, 27]. For intramyocardial
injection,thestandardvolumeof120 llCDCsuspensionwas
injected into two sites of the accessible anterior/anterolateral
infarct border zone. Because of the relatively large volume,
conﬂuence of the injectate from both sites within tissue was
regularly observed. The number of injected CDCs was 2
millioninallcasesofFDG-labeling.Inthegeneticallylabeled
NIS group, 6 of 8 animals received the standard dose of 2
million CDCs. For reasons related to other study topics [26],
one animal received only one million CDCs, and another
animal received 3 million CDCs. The animal protocol was
approved by the institutional animal care and use committee.
Direct CDC labeling with [
18F]FDG, PET imaging
of immediate cell retention
For quantiﬁcation of immediate cell retention at approxi-
mately 1 h after delivery, a previously validated approach
was utilized in 7 rats [27]. In brief, CDCs were incubated
with [
18F]-FDG ex vivo, at a nontoxic activity level. The
syringe, containing no more than 37 kBq (8–30 kBq) of
[
18F]-FDG-labeled CDCs, was imaged for 5 min in a GE
eXplore VISTA small animal scanner (GE Healthcare,
Waukesha, WI, USA), immediately prior to injection.
Radiolabeled CDCs were then injected intramyocardially,
and the empty syringe was imaged again to determine net
injected activity. This was considered to be superior to
dose calibrator measurements because the detection system
was identical to in vivo measurements. Subsequently, the
infarct animal was placed in the scanner and a 60 min scan
of [
18F]-FDG-labeled CDC biodistribution was obtained.
After the completion of cell tracking, 37–55 MBq of
13NH3
were injected intravenously via tail vein and a 20 min static
image of myocardial perfusion was obtained. CT scans
were obtained for attenuation correction. Using volume of
interest (VOI) technique, absolute radioactivity in the
myocardium was quantiﬁed. Early CDC retention was
determined by the fraction of (CDC-derived) myocardial
radioactivity, expressed as percent of injected radioactivity
(i.e. injected number of cells).
This method has been validated against ex vivo poly-
merase chain reaction (PCR) previously [27]. In brief,
CDCs from male donors were injected into the myocar-
dium of 6 female recipients. Animals were sacriﬁced after
1 h, hearts were excised, DNA was isolated and retained
donor cell numbers were quantiﬁed by real-time PCR for
the SRY gene located on the Y chromosome. After testing
in triplicate, the amount of retained cells measured by this
ex vivo technique was 18 ± 12% of injected cells, which
was identical to the results obtained by in vivo FDG
imaging in an albeit separate group of animals [27] (mea-
surements in the same group are impossible because of the
expected rapid cell kinetics and because ex vivo and in
vivo techniques cannot be applied simultaneously). Fur-
thermore, the speciﬁcity of the FDG signal for living cells
has been tested in our prior work. Intramyocardial injection
of an FDG-containing cell lysate resulted in low retention
of injected radioactivity, and ex vivo studies showed that
FDG is stably retained by cells after labeling and thorough
rinsing [27]. Thus, a signiﬁcant contribution of nonspeciﬁc
radioactivity to the FDG signal at the very early time of 1 h
after injection of FDG-labeled cells is unlikely.
Genetic CDC labeling with NIS, SPECT imaging
of 24-h cell engraftment
For measurement of cell engraftment after 24 h, a previ-
ously validated reporter gene based approach was utilized
in eight rats [26]. In brief, a lentiviral vector system was
used to label CDCs, without effect on cell viability
of function. Expression of the human sodium-iodide
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123symporter (hNIS) gene was driven by constitutively active
promoters, namely CAG (composite promoter consisting of
the CMV enhancer and chicken beta actin promoter;
n = 3) in initial studies, and was later switched to cyto-
megalovirus promoter (CMV; n = 5) due to limited
expression under CAG. At 24 h after infarction and CDC
injection, animals were imaged using a Gamma Medica
X-SPECT-CT scanner (Gamma Medica, Northridge, Cali-
fornia). The NIS reporter probe
99mTc (285 ± 63 MBq),
and the perfusion tracer
201Tl (37 ± 11 MBq) were co-
injected via the tail vein. Dual isotope SPECT was
acquired 1 h after tracer injection. Using VOI technique,
the ratio of
99mTc activity at the cell injection site to
bloodpool was measured as a semiquantitative parameter
of the magnitude of cell engraftment [26]. VOIs were
drawn around the maximum of radioactivity at the cell
injection site, excluding areas of the surrounding normally
perfused myocardium or the LV cavity. Background
activity was measured in an area of the myocardium out-
side the VOI but within the perfusion deﬁcit and subtracted
from the VOI activity. A third VOI was then placed at a
location inside the LV cavity, to obtain signal intensity in
the blood pool. All VOI activities were corrected for
attenuation by using CT density images. A contrast
ratio (%) was then deﬁned as 100 9 [(signal in the cells) -
(signal in blood pool)]/signal in blood pool. In order to
correct for differences in promoter strength and injected
cell number, the contrast ratio was then normalized to
injected cell number and to the mean of each promoter
group for subsequent comparison with perfusion. The
resulting percentage of the group mean was taken as a
semi-quantitative measure of relative cell engraftment after
24 h.
Like the FDG-based approach, the NIS-labeling method
has been previously compared to ex vivo PCR measure-
ments of cell engraftment [26]. The same technique as
described above (detection of SRY gene in hearts of female
recipients receiving male donor cells) was used. Four rats
were injected with NIS-labeled CDCs and sacriﬁced at
days 1 and 8. PCR conﬁrmed a rapid cell loss, from
13 ± 4% retention of injected cells on day 1, down to
3 ± 2% on day 8. This matched a loss of the semiquanti-
tative image signal that was found in parallel groups at
serial SPECT imaging after NIS-labeled cell injection [26].
Correction for contamination of perfusion images
by cell-derived radioactivity
In dual isotope SPECT, downscatter of
99mTc-derived
photons into the lower energy
201Tl window may impair
the accuracy of integrated analysis of perfusion and cell
survival. Hence, correction was performed, based on
phantom measurements. A list-mode SPECT scan for a
Tc
99m ﬁlled small sphere, embedded in a water-ﬁlled rat-
sized cylinder, was acquired using the small animal scan-
ner. Data were reconstructed using
201Tl and
99mTc energy
windows, and the ratio of count intensities was determined.
Downscatter from
99mTc to
201Tl windows was measured
as 1.6%. This factor was used for a pixelwise correction of
201Tl perfusion images.
In serially acquired PET images,
13NH3 perfusion
studies were obtained after completion of imaging of [
18F]-
FDG-labeled CDCs. Because the injected dose of
13NH3
was more than thousandfold higher than that of [
18F]-FDG-
labeled cells (37–55 MBq vs. 8–30 kBq), no spillover
effects were expected and no correction was performed.
Polar map analysis of myocardial perfusion
201Tl and
13NH3 perfusion datasets were volumetrically
sampled and polar maps of left ventricular myocardial
activity were generated by previously validated software
[9, 17]. Static polar maps were normalized to their maxi-
mum and a threshold of 60% of the individual maximal
uptake was used to deﬁne the perfusion defect. The per-
fusion defect size was quantiﬁed as the percentage of the
entire polar map, and thus as the percentage of LV myo-
cardium. The myocardial segments deﬁned for perfusion
maps were then transferred to identical locations in the co-
registered cell tracking studies, and a polar map of the cell
signal was obtained. Figure 1 highlights the process for
creating polar maps from static tomographic images of
perfusion and cell signal. The peak signal in cell maps was
used to identify the injection site relative to the perfusion
defect. Based on relative location of the cell signal to the
defect area, the injection was determined as a border zone
injection, if edges of both areas overlapped, as an infarct
injection, if cell signal was completely surrounded by
infarct area, or as a remote injection if cell signal was
completely outside the infarct area. Additionally, a region
of six segments around the peak cell signal was used to
determine residual perfusion (as percent tracer uptake) at
the cell injection site. Three animals (one in the FDG group
and two in the NIS group) had to be excluded from the
latter analysis due to spillover of extracardiac liver activity
into the cell injection site on perfusion images.
Statistical analysis
Values are reported as mean ± standard deviation (SD).
Student’s t test was used to compare continuous variables
between groups. Pearson’s correlation coefﬁcient, along
with Fisher’s r-to-z transformation was used to determine
the relationship between variables. P\0.05 was chosen
for statistical signiﬁcance.
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Similarity of study groups
The perfusion defect as a marker of infarct size was
comparable between
13NH3 PET studies of the early
retention group and
201Tl SPECT studies of the 24-h
engraftment group (37 ± 9%, range 25–53%, for
13NH3;
vs. 38 ± 9%, range 24–55%, for
201Tl; P = NS), con-
ﬁrming comparability of methods and absence of model-
related differences between groups.
CDC signal
In all animals of both groups, the cell signal was visually
detectable and the location was in the infarct border zone in
all cases (Figs. 2, 3). No injection into the infarct center or
remote myocardium was detected by nuclear image anal-
ysis. Due to the limited spatial resolution of nuclear
imaging techniques, the cell signal appeared as a single
spot despite the use of two injection sites. Conﬂuence of
the injected volume from neighboring sites, and partial
volume effects explain this observation. Residual perfusion
at the cell injection site was 48 ± 14% of LV maximum in
the early retention group, and 57 ± 9% in the 24-h
engraftment group (P = NS). Early retention of [
18F]-
FDG-labeled CDCs in the respective group was 20 ± 6%
of injected cells. In absolute terms, this translates into a
retention of 400,000 ± 12,000 CDCs at the intramyocar-
dial injection site, 1 h after injection of 2 Mio CDCs. For
methodological reasons, 24-h engraftment was measured in
relative terms and ranged from 45% below to 75% above
group average.
Relationship between infarct characteristics
and CDC signal
Residual perfusion at the injection site was not related to
immediate cell retention (r =- 0.15; P = 0.8) or 24-h
engraftment (r = 0.12; P = 0.8). Additionally, no signiﬁ-
cant relationship was observed between infarct size and 1-h
CDC retention, although there was a nonsigniﬁcant trend
towards an inverse correlation(r =- 0.65; P = 0.11). In
the 24-h engraftment group, however, there was a signiﬁ-
cant positive correlation between the infarct size and the
reporter probe signal from engrafted cells (r = 0.74;
P = 0.03) (Fig. 4).
Discussion
In summary, noninvasive myocardial imaging was inte-
grated with cell tracking in this project, in order to identify
conditions of the host myocardium which are supportive of
engraftment of therapeutic cells. Our results suggest that a
larger perfusion defect after myocardial infarction is
A  PET Images B  Polar Maps
Perfusion
Labeled CDCs
Perfusion
(13NH3)
Labeled CDCs
(18FDG)
Fusion
Fig. 1 Integration of cell tracking and myocardial perfusion imaging.
a Reangulated tomographic PET images of myocardial perfusion
(
13NH3, grey scale) and [
18F]-FDG-labeled cardiosphere-derived cells
(CDCs; hot metal scale), 1 h after intramyocardial CDC injection in a
rat model of acute myocardial infarction. Fusion images conﬁrm CDC
injection and retention in the hypoperfused apical infarct border zone.
b Matching polar maps of perfusion and the [
18F]-FDG-labeled CDC
signal, created by use of identical search rays. Polar maps are a two-
dimensional displays of three-dimensional tracer distribution through-
out the myocardium, showing anterior wall on top, inferior wall on
bottom, septum on left, lateral wall on right, base in the periphery and
apex in the center
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123associated with a larger amount of CDC engraftment 24 h
after intramyocardial injection into the infarct border zone.
No signiﬁcant relationship between perfusion defect size
and immediate cell retention at 1 h after injection was
observed, although there was an opposite trend towards an
inverse relationship.
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Fig. 2 Polar map analysis of perfusion defect and early retention of
[
18F]-FDG-labeled cardiosphere-derived cells. Shown are polar maps
of PET images in representative infarct animal with a large (a) and
small (b) infarct. Polar maps of myocardial perfusion (left, measured
by
13NH3), the co-registered cell signal (middle), and of a result map
showing the perfusion defect in blue and the cell location in green
(right) are displayed. Note that the cell signal is located in the infarct
border zone in both cases. Consistent with analysis of the entire
group, quantitative cell signal strength is not signiﬁcantly different
between animals but tends to be lower in the larger infarct
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Fig. 3 Polar map analysis of perfusion defect and 24-h engraftment
of NIS-labeled cardiosphere-derived cells. Shown are polar maps of
SPECT images in representative infarct animal with a large (a) and
small (b) infarct. Polar maps of myocardial perfusion (left, measured
by
201Tl), the co-registered cell signal (middle, obtained by injection
of the reporter probe
99mTc), and of a result map showing the
perfusion defect in blue and the cell location in green (right) are
displayed. Note that the cell signal is located in the infarct border
zone in both cases. Consistent with analysis of the entire group, and in
contrast to early retention (Fig. 2), semiquantitative cell signal
strength is higher in the larger infarct
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123CDCs, which are found in adult myocardium, were used
for cell delivery in this study. These cells can be isolated
from myocardial biopsies and they can be expanded in
vitro [24]. Their potential for myocardial regeneration has
been demonstrated in mice, where CDCs improved left
ventricular function after myocardial infarction [24], in rats
after acute myocardial infarction [4], and in a porcine
model of ischemic cardiomyopathy, where CDC injection
resulted in a reduction of infarct size and reduced adverse
remodeling [11]. Our prior experience has shown that
CDCs can be efﬁciently labeled with [
18F]-FDG and with
reporter genes, for detection at different time points and
under various conditions [4, 5, 26, 27]. Our prior work in
rats also showed that intravenously injected CDCs are
mostly retained in lungs and that CDCs injected into the
LV cavity after aortic clamping distribute diffusely in the
entire myocardium [5]. Consequentially, because selective
infusion into the infarct vessel (the most popular clinical
technique) is not feasible in small animals, we chose
intramyocardial injection as the best technique to target
cells to the infarct border zone in our rat model. The setup
used in this report has therefore been extensively validated.
The novelty of the present study lies in its additional
information about effects of the host tissue on CDC sur-
vival, derived from integrated noninvasive imaging.
Interestingly, immediate retention of CDCs after intra-
myocardial injection, as measured by direct labeling with
[
18F]-FDG, was not signiﬁcantly associated with any
perfusion parameter. Visual analysis and quantitatively
measured residual perfusion at the cell location conﬁrm
injection into the infarct border zone in our animals. The
consistent location of injection, and the lack of correlation
between residual perfusion and cell signal provide evi-
dence against a confounding effect of the injection site in
our results. Immediate retention may thus be determined
mostly by mechanical factors such as myocardial contrac-
tion and injection technique. Consistently, a recent study
showed that mechanical interventions such as sealing of the
injection site with ﬁbrin glue or global reduction of con-
tractility by adenosine can be used during the intramyo-
cardial injection to enhance early CDC retention [27].
In contrast to immediate retention, the 24 h engraftment
of CDCs, as measured by the intensity of the NIS reporter
gene signal, showed a signiﬁcant, positive correlation with
cell engraftment. This supports the notion that the myo-
cardial host tissue environment inﬂuences the survival of
transplanted cells, and it is consistent with a recent human
study using [
111In]-labeled bone marrow cells, where the
cell signal was inversely related with ﬂow reserve and
viability in the infarct area [21]. The perfusion defect size
is a marker of the severity of ischemic damage to the
myocardium. Ischemic damage triggers a variety of
molecular mechanisms which may support the survival and
engraftment of transplanted cells. Hypoxia induces
expression of growth factors and adhesion molecules which
regulate cell trafﬁcking [6]. Additionally, ischemic damage
triggers inﬂammation and extracellular matrix activation,
which in turn support cell migration and angiogenesis [13].
Fig. 4 Regression plots for
perfusion parameters and cell
survival. a Immediate retention
of cells, measured by [
18F]-
FDG-labeling, was not
signiﬁcantly correlated with
infarct size, although there was a
nonsignifcant trend towards
inverse correlation. b 24-h
engraftment of cells, measured
by reporter gene imaging,
showed a signiﬁcant positive
correlation with perfusion defect
size. Cell engraftment was
measured as relative signal
intensity when compared to
group average and normalized to
cell number. c, d Lack of
signiﬁcant correlation of early
cell retention and 24-h
engraftment with the residual
perfusionatthecellinjectionsite
as a measure of injection
location relative to infarct
center. ID injected dose, LV left
ventricle
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imaged noninvasively using molecular imaging techniques
[7, 8, 12, 15, 25]. Future studies may thus focus on a direct,
integrated assessment of the role of these molecular path-
ways, which are activated after myocardial infarction, on
cell engraftment [18, 30]. Identiﬁcation of a molecular
signal from host myocardium which strongly predicts cell
engraftment, may result in the future emergence of novel
diagnostic algorithms which characterize the microenvi-
ronment to guide cell delivery with regards to suitable
patients, optimal time point and optimal myocardial region.
The present study should be seen as a ﬁrst step into this
direction.
Our work also has some clinical implications because it
suggests that large infarcts are more likely to beneﬁt from
cell therapy. Notably, randomized studies using bone-
marrow derived cells for treatment of acute myocardial
infarction suggested that patients with larger infarcts and/or
lower ejection fraction are more likely to beneﬁt from cell
therapy [16, 22, 29]. The current study does not only
provide a rationale for subsequent studies looking into
molecular events in the infarct area which may be specif-
ically linked to cell engraftment. Measurements of infarct
size may also be used for selection of subjects for cell
therapy. Speculatively, an implementation of imaging to
select candidates with large infarcts for cell therapy in
future clinical trials may contribute to achieving better
results and more homogeneous response.
There are some limitations of our work. First, it should
be considered that we used two different groups of animals
to analyze early retention and 24 h engraftment. The power
of such a comparison is inferior to a serial analysis.
However, imaging of [
18F]-FDG labeled cells is restricted
to the early phase after delivery, due to radioactive decay
of the tracer. In addition, reporter gene imaging is not yet
possible very early after cell delivery because cells are still
in an energy-deprived state and will not yet show sufﬁcient
reporter gene activity. A combination of both techniques in
the same cell/animals was considered too challenging for
practical application. Importantly, both approaches of
direct and genetic labeling have been compared against ex
vivo PCR and yielded concordant results [26, 27]. Second,
the genetically labeled group was somewhat inhomoge-
neous because different promoters and injected cell num-
bers were used. In order to overcome this heterogeneity,
which was caused by other research aims that are not
included in the present work, we normalized to cell number
and group average. Correlation of NIS-derived cell
engraftment with infarct size was nevertheless convincing,
and in contrast to PET, which was employed for FDG-
labeled cells, SPECT is not a truly quantitative technique in
general.
Conclusion
A larger infarct results in a more suitable myocardial
environment for engraftment of intramyocardially deliv-
ered cardiosphere-derived cells. This observation encour-
ages further investigation of the effect of myocardial host
tissue conditions on therapeutic cell survival.
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